Aspen Aerogels Inc. (ASPN) stock plummeted 33.62% in pre-market trading on Thursday, following the company's fourth-quarter 2024 financial results and weaker-than-expected guidance for the first quarter of 2025.
While the company reported better-than-expected Q4 revenue and earnings, beating analysts' estimates, the market reacted negatively to Aspen Aerogels' disappointing outlook for Q1 2025. The company provided a Q1 revenue guidance range of $75 million to $95 million, significantly lower than the consensus estimate of $104.22 million. Its Q1 EPS guidance range of ($0.18) to $0.00 also fell short of the consensus estimate of $0.08.
Adding to the stock's pre-market plunge, Aspen Aerogels also announced that it is halting the construction of its Statesboro manufacturing facility, citing the need to focus resources on its existing operations. This decision raised concerns among investors about the company's growth prospects and ability to meet future demand.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。